Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2024-07-10 Regulatory Filings
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a regulatory filing submitted to the BSE and NSE in response to a clarification request regarding a previous announcement about the closure of a manufacturing plant due to regulatory action by the Maharashtra Pollution Control Board. It details the nature of the legal/regulatory action and its impact, fitting the definition of a regulatory filing or legal/regulatory update.
2024-07-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended June 30, 2024. It is addressed to stock exchanges and signed by the company secretary and the registrar and share transfer agent. The document is short (3060 characters) and serves as a compliance certificate rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is primarily a regulatory compliance certificate related to securities dematerialisation and shareholder records. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-07-09 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is an official communication from Aarti Pharmalabs Limited to stock exchanges (BSE and NSE) regarding the reaffirmation of credit ratings by CRISIL Ratings Limited. It includes details of the credit rating, the bank loan facilities rated, and a letter from CRISIL explaining the rating surveillance and validity. The document is a notification about credit rating updates, which falls under the category of Capital/Financing Update as it relates to the company's financing and credit facilities. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or announcement of a report publication. The document length is 7964 characters, which is substantive and contains detailed information about the credit rating reaffirmation, not just a brief announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-06-26 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges regarding the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations. It informs about the trading window closure period around the financial results announcement date but does not contain any financial data, results, or detailed report. The length is only 1090 characters, indicating it is a brief announcement rather than a full report. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement without substantive financial content or report details.
2024-06-26 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding a clarification on the financial results submitted for the quarter and year ended March 31, 2024. It references an email query from the exchange about the format of the financial results and provides the company's response. The document does not contain actual financial statements or detailed financial data but is a regulatory communication clarifying a submission. The length is short (1841 characters), and it serves as a clarification rather than the financial report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-06-18 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the closure of manufacturing activities at the company's Dombivli plant. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an announcement of a significant operational event (plant closure) due to regulatory orders from the Maharashtra Pollution Control Board. The document is short (2620 characters) and does not contain financial statements, detailed financial data, or management discussion. It is not a report but a regulatory announcement about a material event affecting the company. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-05-31 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.